391 related articles for article (PubMed ID: 32340819)
21. Exposure to Neoadjuvant Oxaliplatin-Containing Chemotherapy, Does it Effect Intraperitoneal Hyperthermic Chemotherapy Perfusion?
Mangieri CW; Valenzuela CD; Solsky IB; Erali RA; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2023 Apr; 30(4):2486-2493. PubMed ID: 36484904
[TBL] [Abstract][Full Text] [Related]
22. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI).
van de Vlasakker VCJ; Lurvink RJ; Cashin PH; Ceelen W; Deraco M; Goéré D; González-Moreno S; Lehmann K; Li Y; Moran B; Morris DL; Piso P; Quadros CA; Rau B; Somashekhar SP; Sommariva A; van der Speeten K; Spiliotis J; Sugarbaker PH; Teo MCC; Verwaal VJ; Yonemura Y; Glehen O; de Hingh IHJT
Eur J Surg Oncol; 2021 Nov; 47(11):2888-2892. PubMed ID: 34020808
[TBL] [Abstract][Full Text] [Related]
23. Hyperthermic Intraperitoneal Chemotherapy with Mitomycin C versus Oxaliplatin after Cytoreductive Surgery for the Treatment of Peritoneal Metastases of Colorectal Cancer Origin.
Papageorgopoulou C; Nikolakopoulos K; Seretis C
Chirurgia (Bucur); 2022 Jun; 117(3):266-277. PubMed ID: 35792537
[No Abstract] [Full Text] [Related]
24. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
25. Long term survival analysis after hyperthermic intraperitoneal chemotherapy with oxaliplatin as a treatment for appendiceal peritoneal carcinomatosis.
Masckauchan D; Trabulsi N; Dubé P; Aubé-Lecompte ME; Cloutier AS; Mitchell A; Sideris L
Surg Oncol; 2019 Mar; 28():69-75. PubMed ID: 30851915
[TBL] [Abstract][Full Text] [Related]
26. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
[TBL] [Abstract][Full Text] [Related]
27. Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
Delhorme JB; Sauvinet G; Séverac F; Diab S; Liu D; Rohr S; Romain B; Brigand C
Ann Surg Oncol; 2022 Nov; 29(12):7568-7576. PubMed ID: 35882692
[TBL] [Abstract][Full Text] [Related]
28. Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
Benzaquen E; Wang Y; Wiseman S; Rosenfeld V; Sideris L; Dubé P; Pelletier JS; Vanounou T
Can J Surg; 2021 Mar; 64(2):E111-E118. PubMed ID: 33651573
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.
Sipok A; Sardi A; Nieroda C; King MC; Sittig M; Gushchin V
Int J Surg Oncol; 2018; 2018():1920276. PubMed ID: 30643644
[TBL] [Abstract][Full Text] [Related]
30. Delta peritoneal cancer index (ΔPCI): A new dynamic prognostic parameter for survival in patients with colorectal peritoneal metastases.
Hentzen JEKR; van der Plas WY; Kuipers H; Ramcharan S; Been LB; Hoogwater FJH; van Ginkel RJ; van Dam GM; Hemmer PHJ; Kruijff S
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):590-599. PubMed ID: 31806520
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
32. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
[TBL] [Abstract][Full Text] [Related]
33. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.
Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S
Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495
[TBL] [Abstract][Full Text] [Related]
34. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
35. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
Leung V; Huo YR; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
[TBL] [Abstract][Full Text] [Related]
37. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
[TBL] [Abstract][Full Text] [Related]
38. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
Woeste MR; Philips P; Egger ME; Scoggins CR; McMasters KM; Martin RCG
J Surg Oncol; 2020 Jun; 121(8):1298-1305. PubMed ID: 32239529
[TBL] [Abstract][Full Text] [Related]
39. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
40. The impact of postoperative complications following cytoreductive surgery combined with oxaliplatin based heated intraperitoneal chemotherapy.
Verwaal VJ; Funder JA; Sørensen MM; Iversen LH
Eur J Surg Oncol; 2022 Jan; 48(1):183-187. PubMed ID: 34474946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]